Ryvu Therapeutics Presents Recent Data from Multiple Oncology Programs at AACR 2021
Current TAP Partner
Krakow, Poland – March 11, 2021 – Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, announced today that its data from multiple oncology programs will be presented at the upcoming American Association of Cancer Research (AACR) Virtual Annual Meeting 2021, April 10-15 and May 17-21.
Data presented will include results from the RVU120 (SEL120), a CDK8/CDK19 inhibitor program, as well as data from small-molecule STING agonists and HPK1 inhibitor projects.
“We are very excited with the possibility to share data from our most advanced fully-owned oncology program – RVU120 (SEL120) – which is currently in Phase 1b clinical development for the treatment of acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (HRMDS). We made a lot of progress in translational research concerning RVU120 and we look forward to sharing it with the scientific community” – said Krzysztof Brzózka, Chief Scientific Officer at Ryvu Therapeutics.
Details of the e-poster presentations are as follows:
- SEL120, a CDK8/CDK19 inhibitor, possesses strong multilineage differentiation potential in AML: Abstract Number: 1018
- New generation of STING agonists – development and characterization of a novel series of systemic immunomodulators with improved potency: Abstract Number: 1280
- Development and characterization of small molecule HPK1 inhibitors: Abstract Number: 1281
The e-poster website will be launched on Saturday, April 10, which is the first day of the AACR Virtual Annual Meeting.
Additional information is available on the AACR conference website http://www.aacr.org.